forbidden access is denied server error   forbidden access is denied you do not have permission to view this directory or page using the credentials that you supplied urogen pharma appoints fred e cohen md to its board of directorshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets open in  hrs  minssp  dow  nasdaq listenaetnas ceo mark bertolini on the future of the health care systembertolini shares how a lifethreatening injury shaped his views on health careurogen pharma appoints fred e cohen md to its board of directorsglobenewswire•may  reblogsharetweetsharera’anana israel and new york may   globe newswire  urogen pharma ltd urgn a clinical stage biopharmaceutical company developing advanced nonsurgical treatments to address unmet needs in the field of urology with a focus on urooncology announced today the appointment of fred e cohen md dphil to its board of directors dr cohen will also serve on the board’s compensation nomination and governance committeearie belldegrun md urogen pharma’s chairman commented “we are excited to welcome fred to the urogen board of directors  as one of the leaders of tpg’s healthcare efforts over the past decade fred has played an integral part in building many successful biotech companies and brings with him a tremendous trackrecord of creating tangible shareholder value  we look forward to having access to fred’s vast industry experience and his leadership on the board”dr cohen commented “i am excited to be joining urogen’s board of directors  urogen is passionate about changing treatment paradigms in bladder and upper tract carcinomas with the potential to improve the lives of patients this is a pivotal time to be joining the company  i look forward to playing a guiding role in helping urogen to emerge as a leader in urooncology”dr cohen is a senior advisor to tpg capital where he served for over  years as a partner and founder of tpg biotechnology a life science focused venture capital fund  in addition for over two decades throughout his career dr cohen has been affiliated with ucsf where he held various clinical responsibilities including as a research scientist an internist for hospitalized patients a consulting endocrinologist and the chief of the division of endocrinology and metabolism  dr cohen received his bs degree in molecular biophysics and biochemistry from yale university his dphil in molecular biophysics from oxford on a rhodes scholarship and his md from stanford  dr cohen currently serves on the board of directors of several biotechnology and pharmaceutical companiesabout urogen pharma ltdurogen pharma is a clinical stage biopharmaceutical company developing advanced nonsurgical treatments to address unmet needs in the field of urology with a focus on urooncology the company has developed rtgel a proprietary sustained release hydrogelbased formulation for potentially improving the efficacy and safety profiles of existing drugs urogen pharma’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications making local therapy a potentially more effective treatment option urogen pharma’s lead product candidates mitogel and vesigel are designed to potentially remove tumors by nonsurgical means and to treat several forms of nonmuscle invasive urothelial cancer including lowgrade utuc and bladder cancerforward looking statementsthis press release contains forwardlooking statements all statements contained herein other than statements of historical fact constitute forwardlooking statements including statements regarding urogen pharma’s business strategy clinical development plan and operating plans these forwardlooking statements are subject to a number of risks uncertainties and assumptions including but not limited to urogen pharma’s anticipated growth strategies the anticipated trends and challenges in urogen pharma’s business and the markets in which it operates urogen pharma’s ability to attract or retain key management and personnel the size and growth of the potential markets for urogen pharma’s product candidates and its ability to serve those markets and the rate and degree of market acceptance of urogen pharma’s product candidates visàvis alternative therapies moreover urogen pharma operates in a very competitive and rapidly changing environment in which new risks emerge from time to time it is not possible for urogen pharma’s management to predict all risks nor can they assess the impact of all factors on its business or the extent to which any such factor or combination of factors may cause actual results to differ materially from those contained herein in light of these risks uncertainties and assumptions the forwardlooking events and circumstances discussed herein may not occur and urogen pharma’s actual results could differ materially and adversely from those anticipated or implied by the forwardlooking statements contained herein urogen pharma undertakes no obligation to update any such forwardlooking statements after the date hereof to conform to actual results or changes in expectationsread more reblogsharetweetsharerecently viewedyour list is emptywhat to read nextheres trumps approval rating in every statebusiness insiderthe navys newest most sophisticated aircraft carrier doesnt have urinalsbusiness insiderobamacare is hurting these people—and congress is doing nothing about ityahoo financechina is crushing american tech titansyahoo finance videomcdonalds gm and dominos — what you need to know in markets on tuesdayyahoo financefirst ‘avengers infinity war’ trailer leakedinvestorplaceunder armour ripped up jordan spieths old contract before he won his first major and gave him a year deal and its already paid off big timebusiness insiderthe  million conflict that kept scaramucci out of the white house in january has only gotten shadierbusiness insidergoogles forward guidance trumps earnings any day nyse traderyahoo finance videostocks rangebound ahead of big earningsyahoo financethe one question you should always ask in a job interview according to whartons top professorcnbcaetnas ceo mark bertolini on the future of the health care systemyahoo financenew analysis shows north koreas icbm is basically uselessbusiness insidersaudi arabia is cutting oil exports out of desperation nyse traderyahoo finance videoearnings wont matter if q gdp disappoints investorsyahoo financealphabet beats revenue forecast but warns about rising costsreutersdemocrats take aim at big companies in economic blueprinttruth perfect the dems just gave the republicans the white house for the next eight yearsjoin the conversation  k   forbidden access is denied server error   forbidden access is denied you do not have permission to view this directory or page using the credentials that you supplied urogen pharma appoints fred e cohen md to its board of directors nasdaqurgn english français register sign in urogen pharma appoints fred e cohen md to its board of directors may    et  source urogen pharma ra’anana israel and new york may   globe newswire  urogen pharma ltd nasdaqurgn a clinical stage biopharmaceutical company developing advanced nonsurgical treatments to address unmet needs in the field of urology with a focus on urooncology announced today the appointment of fred e cohen md dphil to its board of directors dr cohen will also serve on the board’s compensation nomination and governance committee arie belldegrun md urogen pharma’s chairman commented “we are excited to welcome fred to the urogen board of directors  as one of the leaders of tpg’s healthcare efforts over the past decade fred has played an integral part in building many successful biotech companies and brings with him a tremendous trackrecord of creating tangible shareholder value  we look forward to having access to fred’s vast industry experience and his leadership on the board” dr cohen commented “i am excited to be joining urogen’s board of directors  urogen is passionate about changing treatment paradigms in bladder and upper tract carcinomas with the potential to improve the lives of patients this is a pivotal time to be joining the company  i look forward to playing a guiding role in helping urogen to emerge as a leader in urooncology” dr cohen is a senior advisor to tpg capital where he served for over  years as a partner and founder of tpg biotechnology a life science focused venture capital fund  in addition for over two decades throughout his career dr cohen has been affiliated with ucsf where he held various clinical responsibilities including as a research scientist an internist for hospitalized patients a consulting endocrinologist and the chief of the division of endocrinology and metabolism  dr cohen received his bs degree in molecular biophysics and biochemistry from yale university his dphil in molecular biophysics from oxford on a rhodes scholarship and his md from stanford  dr cohen currently serves on the board of directors of several biotechnology and pharmaceutical companies about urogen pharma ltd urogen pharma is a clinical stage biopharmaceutical company developing advanced nonsurgical treatments to address unmet needs in the field of urology with a focus on urooncology the company has developed rtgel a proprietary sustained release hydrogelbased formulation for potentially improving the efficacy and safety profiles of existing drugs urogen pharma’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications making local therapy a potentially more effective treatment option urogen pharma’s lead product candidates mitogel and vesigel are designed to potentially remove tumors by nonsurgical means and to treat several forms of nonmuscle invasive urothelial cancer including lowgrade utuc and bladder cancer forward looking statements this press release contains forwardlooking statements all statements contained herein other than statements of historical fact constitute forwardlooking statements including statements regarding urogen pharma’s business strategy clinical development plan and operating plans these forwardlooking statements are subject to a number of risks uncertainties and assumptions including but not limited to urogen pharma’s anticipated growth strategies the anticipated trends and challenges in urogen pharma’s business and the markets in which it operates urogen pharma’s ability to attract or retain key management and personnel the size and growth of the potential markets for urogen pharma’s product candidates and its ability to serve those markets and the rate and degree of market acceptance of urogen pharma’s product candidates visàvis alternative therapies moreover urogen pharma operates in a very competitive and rapidly changing environment in which new risks emerge from time to time it is not possible for urogen pharma’s management to predict all risks nor can they assess the impact of all factors on its business or the extent to which any such factor or combination of factors may cause actual results to differ materially from those contained herein in light of these risks uncertainties and assumptions the forwardlooking events and circumstances discussed herein may not occur and urogen pharma’s actual results could differ materially and adversely from those anticipated or implied by the forwardlooking statements contained herein urogen pharma undertakes no obligation to update any such forwardlooking statements after the date hereof to conform to actual results or changes in expectations  contact gary titus urogen pharma ltd  fifth avenue th floor new york ny  garyturogencom  stephanie carrington icr inc  third avenue nd floor new york ny  stephaniecarringtonicrinccom  related articles other press releases by urogen pharma investigational new drug application for rtgel™ in combination with botox® for the treatment of overactive bladder submitted to fda by allergan july    urogen pharma to ring the nasdaq stock market opening bell june    urogen pharma to present at the jefferies  global healthcare conference may    urogen pharma announces two data presentations related to its clinical stage urooncology candidates at the american urology association  annual meeting may    urogen pharma announces closing of initial public offering and exercise of underwriters’ option may     other news releases in directors and officers in the last  days profile urogen pharma   subscribe via rss  subscribe via atom  javascript new york new york united states contact data contact gary titus urogen pharma ltd  fifth avenue th floor new york ny  garyturogencom  stephanie carrington icr inc  third avenue nd floor new york ny  stephaniecarringtonicrinccom  contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files urogen pharma logo logo url  copy the link below formats available original medium small newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved insider trading  cohen fred e  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  cohen fred e select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm nana caredx inc cdna cohen fred edirector   direct view option award  pm nana genomic health inc ghdx cohen fred edirector   direct view option award  pm nana biocryst pharmaceuticals inc bcrx cohen fred edirector   direct view option award  pm nana tandem diabetes care inc tndm cohen fred edirector   direct view option award  pm nana caredx inc cdna cohen fred edirector   direct view option award  pm nana genomic health inc ghdx cohen fred edirector   direct view option award  pm nana biocryst pharmaceuticals inc bcrx cohen fred edirector   direct view option award  pm nana caredx inc cdna cohen fred edirector   direct view option award  pm na caredx inc cdna cohen fred edirector   direct view option award  pm nana caredx inc cdna cohen fred edirector   direct view option award  pm nana genomic health inc ghdx cohen fred edirector   direct view option award  am  roka bioscience inc roka cohen fred edirector   direct view option award  pm  veracyte inc vcyt cohen fred edirector   direct view option award  pm na caredx inc cdna cohen fred edirector   direct view option award  pm  genomic health inc ghdx cohen fred edirector   direct view option award  am nana biocryst pharmaceuticals inc bcrx cohen fred edirector   direct view option award  pm  biocryst pharmaceuticals inc bcrx cohen fred edirector   direct view option award  pm na five prime therapeutics inc fprx cohen fred edirector   direct view option award  pm nana caredx inc cdna cohen fred edirector   direct view option award  pm nana genomic health inc ghdx cohen fred edirector   direct view option award  pm nana biocryst pharmaceuticals inc bcrx cohen fred edirector   direct view exercise  pm nana five prime therapeutics inc fprx cohen fred edirector   direct view exercise  pm nana five prime therapeutics inc fprx cohen fred edirector   direct view exercise  pm nana five prime therapeutics inc fprx cohen fred edirector   direct view exercise  pm nana five prime therapeutics inc fprx cohen fred edirector   direct view exercise  pm na five prime therapeutics inc fprx cohen fred edirector   direct view exercise  pm na five prime therapeutics inc fprx cohen fred edirector   direct view exercise  pm na five prime therapeutics inc fprx cohen fred edirector   direct view exercise  pm na five prime therapeutics inc fprx cohen fred edirector   direct view option award  pm nana caredx inc cdna cohen fred edirector   direct view option award  pm nana genomic health inc ghdx cohen fred edirector   direct view option award  pm nana biocryst pharmaceuticals inc bcrx cohen fred edirector   direct view option award  pm nana tandem diabetes care inc tndm cohen fred edirector   direct view option award  pm nana caredx inc cdna cohen fred edirector   direct view option award  pm nana genomic health inc ghdx cohen fred edirector   direct view option award  pm nana biocryst pharmaceuticals inc bcrx cohen fred edirector   direct view option award  pm nana caredx inc cdna cohen fred edirector   direct view option award  pm nana genomic health inc ghdx cohen fred edirector   direct view option award  pm na roka bioscience inc roka cohen fred edirector   direct view option award  pm na caredx inc cdna cohen fred edirector   direct view option award  pm na five prime therapeutics inc fprx cohen fred edirector   direct view option award  pm  genomic health inc ghdx cohen fred edirector   direct view option award  pm nana biocryst pharmaceuticals inc bcrx cohen fred edirector   direct view option award  pm  biocryst pharmaceuticals inc bcrx cohen fred edirector   direct view option award  pm  veracyte inc vcyt cohen fred edirector   direct view option award  pm nana caredx inc cdna cohen fred edirector   direct view option award  pm nana genomic health inc ghdx cohen fred edirector   direct view option award  pm nana biocryst pharmaceuticals inc bcrx cohen fred edirector   direct view   secformcom all rights reserved archives        tue  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  who we are who we are about us age of evidence leadership executive team board of directors advisors contact us what we do our approach our technology our products overview afirmareg perceptareg envisiatrade publications  abstracts investors overview press releases events  presentations corporate governance executive leadership board of directors committee composition sec filings stock information analyst coverage investor faqs information requests newsroom press releases in the news corporate recognition media resources sign up for news updates join our team our culture job openings search who we are about us age of evidence leadership executive team board of directors advisors contact us what we do our approach our technology our products overview afirmareg perceptareg envisiatrade publications  abstracts investors overview press releases events  presentations corporate governance executive leadership board of directors committee composition sec filings stock information analyst coverage investor faqs information requests newsroom press releases in the news corporate recognition media resources sign up for news updates join our team our culture job openings who we are board of directors executive team board of directors advisors fred e cohen md dphil fred e cohen md dphil facp has served as a director since january   dr cohen is a tpg partner and managing director having joined tpg in  and serves as cohead of tpg’s biotechnology group  dr cohen is also a former member of the faculty at the university of california san francisco where he taught and conducted research from  through   dr cohen also serves as a director of the following public companies  genomic health inc a company focused on providing actionable genomic health information five prime therapeutics inc a clinicstage biotechnology company focused on discovering and developing novel protein therapeutics tandem diabetics care inc a medical device company that designs develops and commercializes products for people with insulindependent diabetes biocryst pharmaceuticals inc a pharmaceutical company focused on the development of novel smallmolecule drugs that block key enzymes involved in infectious and rare diseases roka bioscience inc a food safety diagnostics business and caredx inc a molecular diagnostics business focused on organ transplant recipients he is a member of the institute of medicine of the national academy of sciences and the american academy of arts and sciences  dr cohen holds a bachelor of science degree in molecular biophysics and biochemistry from yale university a dphil in molecular biosphysics from oxford university where he was a rhodes scholar and an md from stanford univeristy biocryst pharmaceuticals inc  board of directors homeabout biocrystcompany overviewpartners  business developmentleadership teamboard of directorscorporate governancecommittee compositioncode of business conductcommittee charterscareersopportunitiesour sciencepipeline  productrapivabnext generation kallikrein inhibitors for haebcxinvestorsanalyst coverageevents  presentationsemail alertsfinancial profileinvestor faqinformation requestnewsproxy onlinesec documentsstock informationcontact irnews  resourceslatest newshae publicationsbcx publications board of directors home  contact us  site map go print this page board of directors board of directors george b abercrombie fred e cohen md dphil stanley c erck nancy hutson phd robert a ingram kenneth b lee jr sanj k patel jon p stonehouse robert a ingram chairman of the board robert a ingram was appointed to the board in august  and was elected chairman of the board in may  mr ingram joined hatteras venture partners a venture capital firm formed to invest primarily in early stage companies with a focus on biopharmaceuticals medical devices diagnostics healthcare it and related opportunities in human medicine as a general partner in january  he began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become ceo and chairman of glaxowellcome a pharmaceutical company he coled the merger and integration that formed glaxosmithkline gsk in december  he subsequently served as the chief operating officer and president of pharmaceutical operations at gsk from january  to january  he served as vice chairman pharmaceuticals of gsk acting as a special advisor to gsk’s corporate executive team until january   mr ingram serves as chairman of the board of novan inc a pharmaceutical company and as lead independent director of cree inc a manufacturer of semiconductor lightemitting diode materials and devices mr ingram also serves as a member of the board of directors of hbm healthcare investments ltd a publicly traded swiss investment company and of malin corporation plc a publicly traded life sciences company based in ireland mr ingram also serves as chairman of viamet pharmaceuticals inc a private company focused on antiinfective research and a director of phasebio pharmaceuticals inc a private clinicalstage biopharmaceutical company mr ingram graduated from eastern illinois university with a bs degree in business administration in addition to his professional responsibilities mr ingram formed and chaired the ceo roundtable on cancer at the request of former president george h w bush and he is a member of numerous other civic and professional organizations mr ingram is a member of the boards for the james b hunt jr institute for educational leadership and policy ceo roundtable on cancer research triangle institute research triangle foundation and chairman north carolina glaxosmithkline foundation mr ingram’s extensive experience in the pharmaceutical industry as both an executive and director and his private investment expertise contribute valuable insight and expertise to the board back to top george b abercrombie george b abercrombie was appointed to the board in october  mr abercrombie has over  years of experience as a business leader in the pharmaceutical industry he most recently served from  to  as the president and chief executive officer of hoffmannla roche inc a pharmaceutical company where he was responsible leading operations in both the us and canada during his tenure mr abercrombie also served as a member of the roche pharmaceutical executive committee which was responsible for developing and implementing global strategy for the pharmaceuticals division in  mr abercrombie joined glaxo wellcome inc as vice president and general manager of the glaxo pharmaceuticals division and was later promoted to senior vice president us commercial operations prior to joining glaxo he spent over ten years at merck  co inc where he gained experience in sales and marketing executive sales management and business development mr abercrombie began his career as a pharmacist after receiving a bachelor’s degree in pharmacy from the university of north carolina at chapel hill and later earned an mba from harvard university mr abercrombie currently holds the position of senior vice president and chief commercial officer at innoviva inc a publicly traded biopharmaceutical asset management company he also serves on the board of brickell biotech a private pharmaceutical company additionally he is an adjunct professor at duke university’s fuqua school of business and a board member of the north carolina glaxosmithkline foundation mr abercrombie’s executive experience in the pharmaceutical industry and management positions with major pharmaceutical companies provide an excellent background for service on the board back to top fred e cohen md dphil fred e cohen md dphil was appointed to the board in july  in  dr cohen joined tpg capital a private investment firm to initiate and lead tpg’s venture efforts in biotechnology and life sciences he retired from this role at the end of  and now serves as a senior advisor to tpg beginning in  and until his retirement in  dr cohen served as a member of the faculty of university of california san francisco ucsf at ucsf dr cohen served as an internist for hospitalized patients a consulting endocrinologist and as the chief of the division of endocrinology and metabolism his research interests include structure based drug design prion diseases computational biology and heteropolymer chemistry dr cohen received his bs degree in molecular biophysics and biochemistry from yale university his dphil in molecular biophysics from oxford on a rhodes scholarship his md from stanford and his postdoctoral training and postgraduate medical training in internal medicine and endocrinology at ucsf he is a fellow of the american college of physicians and the american college of medical informatics and a member of the american society for clinical investigation and association of american physicians dr cohen was elected to the institute of medicine of the national academy of sciences in  and the american academy of arts and sciences in  currently dr cohen also serves on the board of directors of genomic health inc veracyte inc tandem diabetes care inc five prime therapeutics inc roka bioscience inc urogen pharma ltd and caredx inc as well as on the boards of several privately held companies dr cohen’s extensive expertise in the pharmaceutical industry private investment expertise and experience serving on boards of biotechnology companies contribute valuable insight and experience to the board back to top stanley c erck stanley c erck was appointed to the board in december  mr erck has over  years of executive leadership experience in the pharmaceutical industry mr erck has served as president ceo and director of novavax inc a publicly traded biopharmaceutical company since  having previously served as executive chairman from  to  and he has served as a director of novavax since  from  through  mr erck served as president and chief executive officer of iomai corporation a biopharmaceutical company leading the company through an initial public offering and a merger with intercell ag an austrian vaccine company and through the development of a latestage infectious disease product candidate prior to iomai mr erck served as president and chief executive officer of procept inc a publicly traded immunology company as vice president corporate development at integrated genetics inc now genzyme corp and in management positions within baxter international inc in addition to novavax mr erck currently sits on the board of directors of maxcyte inc a publicly traded company developing cell based medicines he received his undergraduate degree from the university of illinois and his mba from the university of chicago graduate school of business mr erck’s executive experience in the biotech industry and his management positions with major pharmaceutical companies including his experience with latestage product candidate development provide an excellent background for service on the board back to top nancy hutson phd dr hutson was appointed to the board in january  bringing over  years of experience as a seasoned professional and leader within the pharmaceutical industry she retired from pfizer inc in  after spending  years in several research and leadership positions most recently serving as senior vice president of global research  development rd as well as director of pfizer’s pharmaceutical rd site grotonnew london laboratories currently dr hutson currently serves on the board of directors for cubist pharmaceuticals inc and endo international plc the scientific advisory board of hatteras venture partners and is an active member on the board of directors for planned parenthood of connecticut she is also involved in several professional societies including but not limited to the american association for the advancement of science and the american physiological society dr hutson received a bachelor of arts degree from illinois wesleyan university and a phd in physiology from vanderbilt university back to top kenneth b lee jr kenneth b lee jr was appointed to the board in june  mr lee has over  years of experience counseling management teams boards of directors and investors of technologybased companies worldwide he is currently a general partner with hatteras venture partners llc a venture capital fund focusing on life science companies which he joined in  previously he was president of am pappas  associates llc following  years with ernst  young llp where he was most recently managing director of the firm’s health sciences corporate finance group and at one time served as the national director of the life sciences practice mr lee received a bachelor of arts degree from lenoirrhyne college and an mba from the university of north carolina at chapel hill mr lee is currently on the board of directors of aralez inc and serves on the board of a private company clinipace previously mr lee served on the boards of abgenix cv therapeutics inspire pharmaceuticals maxygen osi pharmaceuticals and clinverse he has served in various leadership capacities on these boards including chairman of the board independent lead director and chairman of audit and compensation committees mr lee’s experience advising biotechnology companies regarding financial and partnering strategies his extensive background in finance and his experience serving on the boards of biotech companies contribute valuable insight and experience to the board back to top sanj k patel sanj k patel is the chairman and ceo of kiniksa pharmaceuticals which was formed in  to develop therapies for patients with devastating diseases and unmet medical need he brings more than  years of experience in the pharmaceutical and biotech industries and has a combination of scientific clinical and commercial skills sanj k patel created synageva in june  to focus on rare diseases and designed and initiated its lead program kanuma® for lysosomal acid lipase deficiency lal deficiency in july  kanuma was approved globally in  as the first therapy for patients suffering from lal deficiency he took the company public on the nasdaq global market in november  and raised over  billion in capital in less than  years in june  synageva was sold to alexion pharmaceuticals for b including cash which represented the highest premium ever paid for a biotech company valued over b prior to synageva he was at genzyme corporation  where most recently he was the head of us sales marketing and commercial operations for genzyme therapeutics franchise and led the us launch of myozyme® in addition to sales and marketing responsibility for cerezyme® fabrazyme® and aldurazyme® previously sanj held several crossfunctional senior leadership roles at genzyme including vice president clinical research and head of the global clinical research operations council for all genzyme divisions including therapeutics oncology and transplant he was responsible for clinical operations and development for all crossbusiness genzyme products and was instrumental in the path to commercialization of several treatments notably sanj led the fabrazyme® clinical operations team and development program to fda approval in april  prior to genzyme sanj held roles in clinical research and commercial operations with increasing levels of responsibility at burroughs wellcome hoechst marrion roussel and fujisawaotsuka pharmaceuticals sanj obtained his bsc with honors in biotechnology from the university of the south bank london he completed his management and business studies at ealing college london and his pharmacology research program at the wellcome foundation sanj is a member of the board of directors for syros pharmaceuticals and biocryst pharmaceuticals both publicly traded biotechnology companies he is also the founder and director of the sanj k patel and family foundation a philanthropic organization that supports various charities supporting patients with rare and devastating diseases back to top jon p stonehouse jon p stonehouse joined biocryst in january  as chief executive officer and director he was also named president in july  prior to joining the company he served as senior vice president of corporate development for merck kgaa a pharmaceutical company since july  his responsibilities included corporate mergers and acquisitions global licensing and business development corporate strategy and alliance management prior to joining merck kgaa mr stonehouse held a variety of roles at astra merckastrazeneca mr stonehouse began his career in the pharmaceutical industry as a sales representative and held increasing sales leadership positions at merck  co inc in  and  respectively mr stonehouse joined the advisory boards of precision biosciences inc a private biotechnology company and genscript a private bioservices company also in december  he joined the board of directors of bellicum pharmaceuticals inc a publicly traded clinical stage biopharmaceutical company focused on novel cellular immunotherapies mr stonehouse earned his bs in microbiology at the university of minnesota as chief executive officer and president of biocryst mr stonehouse brings to the board an intimate knowledge of our business and his executive experience in a variety of capacities at major pharmaceutical companies provides industryspecific operational experience that is beneficial to the board back to top